Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | protease, serine, 3 | Starlite/ChEMBL | References |
Homo sapiens | coagulation factor X | Starlite/ChEMBL | References |
Homo sapiens | protease, serine, 1 (trypsin 1) | References | |
Homo sapiens | protease, serine, 2 (trypsin 2) | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Trypsin family protein | protease, serine, 1 (trypsin 1) | 247 aa | 287 aa | 21.6 % |
Schistosoma mansoni | cercarial elastase (S01 family) | protease, serine, 3 | 261 aa | 234 aa | 25.2 % |
Schistosoma mansoni | cercarial elastase (S01 family) | protease, serine, 2 (trypsin 2) | 247 aa | 240 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.2409 | 1 | 1 | |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2409 | 1 | 1 |
Brugia malayi | Trypsin family protein | 0.0344 | 0.0121 | 0.5 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.2409 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2409 | 1 | 1 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.1422 | 0.5276 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1422 | 0.5276 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2369 | 0.9805 | 0.9706 |
Mycobacterium ulcerans | hypothetical protein | 0.1422 | 0.5276 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2369 | 0.9805 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.2369 | 0.9805 | 0.9803 |
Loa Loa (eye worm) | hypothetical protein | 0.1381 | 0.5081 | 0.5021 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2369 | 0.9805 | 0.9706 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.1422 | 0.5276 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2409 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2409 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.1422 | 0.5276 | 0.5 |
Onchocerca volvulus | 0.0344 | 0.0121 | 0.0121 | |
Schistosoma mansoni | 6-phosphofructokinase | 0.2409 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.2369 | 0.9805 | 0.9706 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2409 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED200 (functional) | = 7 uM | The Anti-coagulant activity was tested by measuring activated partial thromboplastin time (aPTT) | ChEMBL. | 9836616 |
ED200 (functional) | = 7 uM | The Anti-coagulant activity was tested by measuring activated partial thromboplastin time (aPTT) | ChEMBL. | 9836616 |
ED200 (functional) | > 500 uM | The Anti-coagulant activity was tested by measuring thrombin clotting time (TT) | ChEMBL. | 9836616 |
ED200 (functional) | > 500 uM | The Anti-coagulant activity was tested by measuring thrombin clotting time (TT) | ChEMBL. | 9836616 |
Ki (binding) | = 0.026 uM | Binding affinity of the compound against Coagulation factor X | ChEMBL. | 10669559 |
Ki (binding) | = 0.026 uM | The inhibition constant against human Coagulation factor X | ChEMBL. | 9836616 |
Ki (binding) | = 0.026 uM | Binding affinity of the compound against Coagulation factor X | ChEMBL. | 10669559 |
Ki (binding) | = 0.026 uM | The inhibition constant against human Coagulation factor X | ChEMBL. | 9836616 |
Ki (binding) | = 0.2 uM | The inhibition constant of the compound against human trypsin | ChEMBL. | 9836616 |
Ki (binding) | = 0.2 uM | The inhibition constant of the compound against human trypsin | ChEMBL. | 9836616 |
Ki (binding) | > 100 uM | The inhibition constant against human thrombin | ChEMBL. | 9836616 |
Ki (binding) | > 100 uM | The inhibition constant against human thrombin | ChEMBL. | 9836616 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.